The control of physicochemical and biological properties of proteins is a
major challenge in all biotechnology sectors. Indeed,
proteins are
increasingly used as catalysts for their high specificity and performance in
the development of environmentally
friendly bioprocesses. In addition,
therapeutic proteins, monoclonal antibodies and protein vaccines are of key
importance for the
biopharmaceutical field. With the rise of structural
bioinformatics, it becomes feasible to rationally design optimized
biological
molecules. Even though the in silico approaches cannot lead to ideal
success rates given the extreme complexity of biological
systems, they
make it nevertheless possible to propose a limited number of candidate
molecules to be validated experimentally.
This drastically reduces the
number of experiments, which has a series of positive effects such as
reduced costs, decrease and
better targeting of animal experimentation,
and the advent of a general technology that is more compatible with
sustainable
development.